Triptorelin

Overview

Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men.

Indication

Triptorelin is indicated for the palliative treatment of advanced prostate cancer.

Associated Conditions

Advanced Prostate Cancer

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Study on Human Bioequivalence of Triprerelin Acetate for Injection	2024/11/11	NCT06683066	Phase 1	Recruiting	The Affiliated Hospital of Qingdao University
Adenomyosis and Pregnancy: Levonorgestrel vs. GnRH for Blastocyst Transfer	2024/09/03	NCT06581679	Not Applicable	Completed	Zagazig University
Effect GnRH Agonist Administration in Endometriosis Cyst Patients	2024/07/29	NCT06525155	Phase 3	Recruiting	Rumah Sakit Pusat Angkatan Darat Gatot Soebroto
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer	2024/07/22	NCT06513962	Phase 3	Recruiting	Children's Oncology Group
Efficacy, Metabolism and BMD of the 3-month TP Compared to the 1-month TP in ICPP	2024/07/05	NCT06487143	Phase 4	Not yet recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients	2024/06/25	NCT06473259	N/A	Recruiting	Santa Chiara Hospital
Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial	2024/04/23	NCT06378866	Phase 2	Recruiting	Mayo Clinic
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers	2024/02/28	NCT06282588	Phase 2	Recruiting	Cancer Research Antwerp
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)	2023/11/13	NCT06129539	Phase 3	Recruiting	Debiopharm International SA
Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer	2023/08/08	NCT05982093	Phase 2	Active, not recruiting	SOLTI Breast Cancer Research Group

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
DECAPEPTYL INJECTION 0.1 mg/ml	FERRING GMBH	SIN08697P	INJECTION	100 mcg/ml	5/6/1996
DIPHERELINE P.R. POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION 3.75 mg/vial	IPSEN PHARMA BIOTECH (Lyophilisate manufacturer), CENEXI (Solvent manufacturer), Ipsen Pharma Biotech (Gamma irradiation site of lyophilisate), Sterigenics Italy S.P.A (Gamma irradiation site of lyophilisate), Sterigenics Belgium (Gamma irradiation site of lyophilisate)	SIN14634P	INJECTION, POWDER, FOR SUSPENSION, EXTENDED RELEASE	3.75 mg/vial	9/25/2014
Pamorelin Powder for Suspension for Injection 11.25 mg per vial	Debiopharm Research & Manufacturing SA, Synergy Health Daniken AG (Contract Sterilization Facility)	SIN14324P	INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION	11.25 mg	3/11/2013
Pamorelin Powder for Suspension for Injection 22.5 mg per vial	Debiopharm Research & Manufacturing SA, Synergy Health Daniken AG (Contract Sterilization Facility)	SIN14325P	INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION	22.5 mg	3/11/2013
Pamorelin Powder for Suspension for Injection 3.75 mg per vial	Debiopharm Research & Manufacturing SA, Synergy Health Daniken AG (Contract Sterilization Facility)	SIN14323P	INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION	3.75 mg	3/11/2013
DIPHERELINE P.R. POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION 11.25 mg/vial	IPSEN PHARMA BIOTECH (Lyophilisate manufacturer), CENEXI (Solvent manufacturer), Ipsen Pharma Biotech (Gamma Irradiation site of lyophilisate), Sterigenics Italy S.P.A (Gamma Irradiation site of lyophilisate), Sterigenics Belgium (Fleurus) SA (Gamma irradiation site of lyophilisate)	SIN14635P	INJECTION, POWDER, FOR SUSPENSION, EXTENDED RELEASE	11.25 mg/vial	9/25/2014
DECAPEPTYL CR FOR INJECTION 3.75 mg/syringe	FERRING GMBH	SIN09105P	INJECTION, POWDER, FOR SOLUTION	3.75 mg/syringe	12/28/1996

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
DIPHERELINE triptorelin {as embonate} 11.25mg powder for suspension vial and water for injections ampoule	109856	Ipsen Pty Ltd	Medicine	A	8/28/2006
DIPHERELINE triptorelin (as embonate) 3.75 mg powder for suspension vial and water for injections ampoule	109854	Ipsen Pty Ltd	Medicine	A	8/28/2006
DIPHERELINE triptorelin (as embonate) 22.5 mg powder for suspension vial and water for injections ampoule	159173	Ipsen Pty Ltd	Medicine	A	7/27/2010
DECAPEPTYL triptorelin acetate 100 micrograms/1 mL solution for injection in 1mL pre-filled syringe with integrated needle	219857	Ferring Pharmaceuticals Pty Ltd	Medicine	A	3/4/2015

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
DECAPEPTYL	Ferring Inc	02389282	Solution - Subcutaneous	0.1 MG / ML	8/9/2012

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
DECAPEPTYL TRIMESTRAL 11,25 MG POLVO Y DISOLVENTE PARA SUSPENSION DE LIBERACION PROLONGADA INYECTABLE	Ipsen Pharma S.A.	61665	POLVO Y DISOLVENTE PARA SUSPENSIÓN INYECTABLE	Medicamento Sujeto A Prescripción Médica	Commercialized
DECAPEPTYL MENSUAL 3,75 MG POLVO Y DISOLVENTE PARA SUSPENSION DE LIBERACION PROLONGADA INYECTABLE	Ipsen Pharma S.A.	58404	POLVO Y DISOLVENTE PARA SUSPENSIÓN INYECTABLE	Medicamento Sujeto A Prescripción Médica	Commercialized

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

CriteriaMapper Automates Clinical Trial Cohort Identification Using EHR and NLP

10 months ago

• A new system called CriteriaMapper automates the identification of clinical trial cohorts by integrating data from electronic health records (EHR) and natural language processing (NLP). • The system normalizes eligibility criteria (EC) attributes and clinical characteristics across seven domains, including conditions, procedures, lab tests, therapies, biomarkers, observations, and diagnosis modifiers. • CriteriaMapper uses rule-based knowledge engineering and standard terminologies to map EC attributes to clinical characteristics in EHRs, enhancing the efficiency and accuracy of patient matching for clinical trials. • The system's performance was evaluated using inter-rater agreement and comparisons against a gold standard derived from EHR data, demonstrating its reliability for clinical phenotyping.

Short-Term ADT Plus High-Dose Radiotherapy Improves Outcomes in Localized Prostate Cancer

a year ago

A phase 3 trial (GETUG 14) reveals that combining short-term androgen deprivation therapy (ADT) with high-dose radiotherapy improves disease-free survival in localized prostate cancer patients.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access